Back

Benefits and evolving insights on SGLT2i in the spectrum of LVEF: can we set priorities?

22 May 2022 (18:00 - 18:10)
Organised by:
Congress Presentation Part of: When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options Treatment Open Access Heart Failure 2022

About the speaker

Photo
Professor Carolyn S P Lam

Duke-NUS Graduate Medical School Singapore, Singapore (Singapore)

3 More presentations in this session

Presentation thumbnail
The clinical challenges of initiating guideline-recommended therapy in HFrEF.
Professor J. McMurray (Glasgow, GB)
Slides Video
Presentation thumbnail
Expanding evidence on SGLT2i: where are we now and what can we expect?
Professor S. Solomon (Boston, US)
Slides Video
Presentation thumbnail
Expert panel: What are the implications for our practice?
Professor J. McMurray (Glasgow, GB) Professor S. Solomon (Boston, US) Professor C. Lam (Singapore, SG)
Slides Video

Access the full session

Session thumbnail
When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options
Video

The Event

Event poster

Heart Failure 2022

22 May 2022 18:00 CET
You may be interested in
thumbnail
Congress Presentation
A patient with HF and LVEF > 40%: SGLT2 inhibitors.
27 August 2022
thumbnail
Congress Presentation
SGLT2 inhibitors: major cardiovascular outcomes in ambulatory patients with HFrEF.
21 May 2022
thumbnail
Congress Session
SGLT2 inhibitors in practice (part 1): what is the state of heart failure treatment in 2022?
26 August 2022
thumbnail
Congress Presentation
SGLT2 inhibition across the spectrum of ejection fraction - the time for implementation is now!
20 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources